– New Patient Screening for Phase 3 SENTRY Trial in Myelofibrosis Expected to Close This Week; Top-Line Results Anticipated in March 2026 – – Total Revenue was $37.9 Million; U.S. XPOVIO® (selinexor) Net Product Revenue was $29.7 Million, up 6% compared to Second Quarter of 2024 – –...
Related Questions
What is the market's expected reaction to the upcoming top‑line results from the Phase 3 SENTRY trial in March 2026?
How will the closure of patient screening for the SENTRY trial this week affect short‑term cash flow and operating expenses?
What guidance is Karyopharm providing for future revenue growth beyond the 6% increase in XPOVIO® net product revenue?
How does the 6% YoY growth in XPOVIO® revenue compare to analyst expectations and to performance of similar oncology drugs?
What is the projected impact of the SENTRY trial results on the valuation of Karyopharm’s pipeline and overall enterprise value?
Are there any anticipated dilution effects from potential equity raises to fund the Phase 3 trial or other development programs?
What are the key risks that could delay or negatively affect the March 2026 top‑line results from the SENTRY trial?
How does Karyopharm's total revenue of $37.9 million compare with consensus estimates for Q2 2025?
What is the expected timeline for any potential regulatory submissions or approvals related to selinexor following the trial outcomes?
How might the trial progress and revenue trends influence short‑term technical indicators and trading volume for KPTX?